BioCardia, Inc. (NASDAQ:BCDA) shares are losing ground on Tuesday. The downside comes just a day after the clinical-stage biopharmaceutical firm announced a capital raise, triggering common stock dilution concerns among retail traders. Nasdaq futures are up 0.84% while S&P 500 futures have gained 0.48%.
Share Dilution Pulls BioCardia Stock Lower
The primary catalyst behind the Tuesday drop is a $4.4 million financing arrangement announced by the company on Monday. According to the corporate statement, BioCardia sold 3,509,604 shares on Friday, at an average fixed price of $1.279 per share.
While the company issued no new warrants during this capital raise, the influx of millions of new shares into the open market often dilutes existing equity value, sparking immediate downward price momentum.
Wall Street Analyst Reiterates Buy
Despite the immediate sell-off, HC Wainwright & Co. remains bullish on the Sunnyvale, California-based developer. The firm reiterated its Buy rating on BioCardia and maintained a $25 price forecast.
The funding round closely follows a Friday rally where BCDA shares gained 45.71% to hit $1.20. That surge occurred after the company confirmed that the FDA acknowledged its ongoing CardiAMP Heart Failure II Trial could single-handedly support a Premarket Approval (PMA) pathway.
Critical Levels To Watch for BCDA Stock
The longer-term trend remains bearish: BCDA is trading 14.8% below its 20-day SMA, 24.3% below its 50-day SMA, 29.4% below its 100-day SMA, and 37.7% below its 200-day SMA.
With the 20-day SMA below the 50-day SMA and the 50-day SMA below the 200-day SMA, the moving-average structure still points to a downtrend across multiple timeframes.
Momentum is trying to improve even as price stays weak: MACD is above its signal line and the histogram is positive, which suggests downside pressure is easing versus the prior downswing.
In plain English, when MACD is above its signal line, it often means sellers are losing control—even if the stock hasn’t actually flipped back into an uptrend yet.
From a “levels that matter” standpoint, the stock is also trading below its 52-week low of 84 cents, which can act like an air pocket if buyers don’t step in quickly.
The last notable swing low was in May, and with the 12-month performance down 58.93%, the burden is on bulls to prove a base can form before any moving-average reclaim becomes realistic.
BioCardia Price Action
BCDA Stock Price Activity: BioCardia shares were down 10.82% at $0.82 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
